Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renalytix plc - American Depositary Shares (NQ:RNLX)

0.2071 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Renalytix plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
From Renalytix plc
Via GlobeNewswire
Vail Resorts, NIO And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Markets Turn Bullish After Dow Rises For Third Straight Session
The CNN Money Fear and Greed index showed an improvement in overall sentiment among U.S. investors on Thursday. U.S. stocks closed higher on Thursday following the release of initial jobless claims... 
Via Benzinga
Earnings Preview For Renalytix
Via Benzinga
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
From Renalytix plc
Via GlobeNewswire
Renalytix AI Earnings Preview
Via Benzinga
Preview: Renalytix AI's Earnings
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for a look at the biggest pre-market stock movers on Tuesday morning with all the details traders need to know about! 
Via InvestorPlace
Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage 
From Renalytix plc
Via GlobeNewswire
New Published Real-World Evidence Shows KidneyIntelX™ Utility
From Renalytix plc
Via GlobeNewswire
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
From Renalytix plc
Via GlobeNewswire
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
From Renalytix plc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Renalytix plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. 
Via Benzinga
Renalytix announces a c.$20.3 million private placement
From Renalytix plc
Via GlobeNewswire
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease 
From Renalytix plc
Via GlobeNewswire
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease 
From Renalytix AI, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patients 
From Renalytix AI, Inc.
Via GlobeNewswire
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
From Renalytix AI, Inc.
Via GlobeNewswire
Earnings Scheduled For November 30, 2022
Companies Reporting Before The Bell • Seadrill (NYSE:SDRL) is expected to report earnings for its third quarter. • Build-A-Bear Workshop (NYSE:BBW) is likely to report earnings for its third quarter. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
From Renalytix AI, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.